Vagal Blocking Improves Glycemic Control and Elevated Blood Pressure in Obese Subjects with Type 2 Diabetes Mellitus
% EWL and change in glycemic parameters (mg/dL) and blood pressure (mmHg) from baseline over 12 months.
Time following device activation—change from baseline
MAP, all subjects (mmHg),
SBP, all subjects (mmHg),
DBP, all subjects (mmHg),
MAP elevated (mmHg),
SBP elevated (mmHg),
DBP elevated (mmHg),
At 1, 4, and 12 weeks and 6 months; at 4 weeks, 12 weeks and 6 months; at 1 week, 12 weeks and 6 months; *at 12 weeks. FPG: fasting plasma glucose, MAP: mean arterial pressure, SBP: systolic blood pressure, and DBP: diastolic blood pressure.
Article of the Year Award: Outstanding research contributions of 2020, as selected by our Chief Editors. Read the winning articles.